Epigenetics: Unwrapping the Future for Drug Discovery?
Bentley University
Waltham, MA
Thursday, October 20, 2011
8:00 am - 6:00 pm
Schedule:
| 8:00-9:00 am | Check-in, Light breakfast, / Exhibitor setup |
| 9:00-9:10 am | Opening Remarks Rajvi Chopra, Novartis |
| Session I | Chair: Sharon Townson |
| 9:10-9:55 am | "Defining the Cancer Epigenome and its Potential for Therapeutic
Targeting" Stephen Baylin, The John Hopkins University - School of Medicine |
| 9:55-10:30 am | "Protein Methyltransferase Inhibitors as Personalized Cancer
Therapeutics" Robert Copeland, Epizyme |
| 10:30-11:00 am | Coffee |
| Session II | Chair: Nessa Carey |
| 11:00-11:35 am | "The Intersection of Structural Biology and Epigenetics" Steve Bellon, Constellation Pharmaceuticals |
| 11:35-12:20 pm | "Structural and chemical biology of readers and writers of the
histone code" Cheryl Arrowsmith, SGC - Toronto |
| 12:20-1:10 pm | Lunch |
| Session III | Chair: Elizabeth Sprague |
| 1:10-1:55 pm | "Mechanisms for Coordinated DNA Methylation and Histone
Methylation" Xiaodong Cheng, Emory University School of Medicine |
| 1:55-2:30 pm | "Chemical Inhibition of Bromodomains" James Bradner, Dana Farber Cancer Institute / HMS |
| 2:30-3:00 pm | Coffee |
| Session IV | Chair: Steven Kazmirski |
| 3:00-3:35 pm | "Molecular recognition of nucleosomes by chromatin factors and
enzymes" Song Tan, Penn State University |
| 3:35-4:10 pm | "Structural Basis of Substrate Methylation and Inhibition of
SMYD2" Andrew Ferguson, AstraZeneca |
| 4:10-4:45 pm | "Epigenetic therapies in non-oncology indications - the
opportunities and the challenges" Nessa Carey, Pfizer UK |
| 4:45 pm | Mixer |
Meeting Organizers:
- Steven Kazmirski - AstraZeneca
- Elizabeth Sprague - Novartis
- Sharon Townson - Eleven Biotherapeutics
Meeting Sponsors:
- AstraZeneca
- Cisbio
- Eleven Biotherapeutics
- Formulatrix
- Genewiz
- GenScript
- Novartis
- PerkinElmer
- Pfizer
- Promega
- Rigaku
- Vertex
- XTAL BioStructures